Ceribell, Inc. (CBLL) · Aug 10, 2026 · Earnings

Revenue beat modestly, guidance rose, but losses widened on heavier spending

Revenue beat modestly, guidance rose, but losses widened on heavier spending

The quarter came in slightly ahead on revenue but below on EPS. Ceribell delivered $28.1 million of revenue versus a published consensus of approximately $27.83 million, while its $0.51 per-share loss was worse than the roughly $0.48 expected loss.

MetricQ2 2026Q2 2025Market expectation
Total revenue$28.1 million (Financial Highlights)$21.2 million (Financial Highlights)~$27.83 million
Gross margin92% (Financial Highlights)88% (Financial Highlights)—
Net loss$(19.3) million (Income Statement)$(13.6) million (Income Statement)—
Net loss per share$(0.51) (Income Statement)$(0.38) (Income Statement)~$(0.48)
Adjusted EBITDA loss$(9.8) million (Non-GAAP Reconciliation)$(10.0) million (Non-GAAP Reconciliation)—

Underlying demand was better than the headline numbers suggest. Revenue grew 33% year over year, with product revenue up 33% and subscription revenue up 30%, indicating both new account additions and higher usage from existing customers—not just a one-time product shipment effect. The 92% gross margin was also strong, though it benefited partly from tariff refunds, making the full improvement less repeatable (Financial Highlights).

Management raised the full-year revenue outlook, adding a clearer positive surprise. The new $114 million–$117 million range is above the prior $112 million–$116 million range, implying a modest upward reset to expectations rather than a wholesale change in trajectory. The filing attributes the increase to continued account growth and utilization, consistent with the quarter’s revenue performance (2026 Financial Outlook).

Profitability remains the main constraint. Operating expenses rose 37%, substantially faster than revenue, driven by commercial hiring, product-pipeline investment, stock compensation, and patent litigation. As a result, the GAAP net loss widened to $19.3 million, even though adjusted EBITDA loss improved slightly to $9.8 million; the gap reflects $6.0 million of stock compensation and $3.9 million of IP litigation costs excluded from adjusted EBITDA (Income Statement; Non-GAAP Reconciliation).

The net read is modestly favorable versus expectations, but not cleanly so. A small revenue beat, a guidance increase, and slightly improved adjusted EBITDA outweigh the EPS miss, while FDA clearances, the delirium-monitoring reimbursement effective October 1, 2026, and a new credit facility expand the potential growth runway. However, cash and marketable securities fell to $129.3 million from $159.3 million at year-end, and the new facility adds financing capacity rather than demonstrating reduced cash consumption (Balance Sheets; Financial Highlights).

Original filing on SEC EDGAR

More Ceribell, Inc. news

Revenue beat modestly, guidance rose, but losses widened on heavier spending | CBLL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.